| Disease Domain | Count |
|---|---|
| Infectious Diseases | 6 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 6 |
| Top 5 Target | Count |
|---|---|
| NS2(Non-structural protein 2) | 4 |
| CTSL x cruzain | 2 |
Target |
Mechanism NS2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NS2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NS2 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Jan 2026 |
Sponsor / Collaborator |
Start Date09 Oct 2025 |
Sponsor / Collaborator |
Start Date13 Mar 2025 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
LQM330 ( NS2 ) | Chikungunya Fever More | Preclinical |
LQM336 ( NS2 ) | Chikungunya Fever More | Preclinical |
LQM338 ( NS2 ) | Chikungunya Fever More | Preclinical |
FN-27(Federal University of Alagoas) ( CTSL x cruzain ) | Trypanosomiasis More | Preclinical |
MCG-02(Federal University of Alagoas) ( CTSL x cruzain ) | Trypanosomiasis More | Preclinical |





